Medicinal Acidic Cannabinoids

Abstract

The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.

1 . A method of treating a disease or symptom thereof in an animal in need of such treatment comprising administering in acidic form as an active ingredient an acidic cannabinoid represented by formula Ia or Ib 
       
         
           
           
               
               
           
         
       
       wherein X, Z and A each represent a different group selected from the groups —OH, hydrogen and a first alkyl; 
       wherein R represents a hydrogen, a C n H 2n —OH, a C n H 2n —COOH or a second alkyl;
 and wherein D represents hydroxyl or a third alkyl. 
 
     
     
         2 . The method according to  claim 1 , wherein the acidic cannabinoid is Δ 9 -tetrahydrocannabinolic acid. 
     
     
         3 . The method according to  claim 1 , wherein the disease is inflammatory bowel disease or Crohn's disease. 
     
     
         4 . The method according to  claim 1 , wherein the disease is multiple sclerosis, arthritis, AIDS, an inflammatory skin disease or encephalomyelitis. 
     
     
         5 . The method according to  claim 4 , wherein the inflammatory skin disease is dermatitis or psoriasis. 
     
     
         6 . The method according to  claim 1 , wherein the symptom is associated with cancer, anorexia, AIDS, spasticity, glaucoma or chronic pain. 
     
     
         7 . The method according to  claim 1 , wherein the acidic cannabinoid is used in isolated form. 
     
     
         8 . The method according to  claim 1 , wherein the acidic cannabinoid is orally administered. 
     
     
         9 . The method according to  claim 1 , wherein the acidic cannabinoid is administered by dermal application as a cream or ointment. 
     
     
         10 . The method according to  claim 1 , wherein the acidic cannabinoid is administered in purified form via a nasal or inhalatory route. 
     
     
         11 . The method according to  claim 1 , wherein the acidic cannabinoid is administered as a preparation comprising 0-2 wt. % of Δ 9 -Tetrahydrocannabinol as a weight percentage of the amount of the acidic cannabinoid. 
     
     
         12 . The method according to  claim 11 , wherein the acidic cannabinoid is administered as a preparation that is free of Δ 9 -Tetrahydrocannabinol. 
     
     
         13 . The method according to  claim 1 , wherein the acidic cannabinoid is administered by suppository. 
     
     
         14 . Pharmaceutical preparation comprising an acidic cannabinoid represented by formula Ia or Ib 
       
         
           
           
               
               
           
         
       
       wherein X, Z and A each represent a different group selected from the groups —OH, hydrogen and a first alkyl;
 wherein R represents a hydrogen, a C n H 2n —OH, a C n H 2n —COOH or a second alkyl; 
 and wherein D represents hydroxyl or a third alkyl; 
 and a pharmaceutically acceptable carrier. 
 
     
     
         15 . Pharmaceutical preparation according to  claim 14 , wherein the acidic cannabinoid is Δ 9 -tetrahydrocannabinolic acid. 
     
     
         16 . Pharmaceutical preparation according to  claim 14 , in the form of tinctures, ointments, sprays, inhalants, powders, granules, suppositories, creams, tablets or capsules. 
     
     
         17 . Pharmaceutical preparation according to  claim 14 , which preparation comprises 0-2 wt. % Δ 9 -Tetrahydrocannabinol as a weight percentage of the amount of the acidic cannabinoid. 
     
     
         18 . Pharmaceutical preparation according to  claim 14 , which preparation is free of Δ 9 -Tetrahydrocannabinol.